DPPIV is a multifunctional protein involved in cleaving incretin hormones, hence serving to regulate glucose homeostasis and consequently viewed as a target for the management of Type 2 diabetes
A potential Type 2 diabetes research aid, DPPIV is a multifunctional protein expressed both in a soluble form and as surface protein on several cell types.
It is involved in cleaving incretin hormones of the glucagon family of peptides, and hence serves to regulate glucose homeostasis.
Consequently, it is being viewed as a therapeutic target for the management of Type 2 diabetes.
A new assay for measuring dipeptidyl peptidase IV (DPPIV) activity has been launched by Promega.
The DPPIV-Glo protease assay is a highly sensitive, homogenous, luminescent assay which produces maximum signal in just 30 minutes, and signal strength is maintained for several hours.
The homogeneous add-mix-measure format makes it amenable to automation.
The DPPIV-Glo protease assay can detect as little as 1pg/ml of DPPIV and is therefore far more sensitive than fluorescent DPPIV assays which suffer from inherent background signal, says Promega.
Based on proprietary Ultra-Glo recombinant luciferase, a stable light signal is generated across a wide range of assay conditions.
The assay is extremely robust, demonstrating a Z' factor of 0.77 when used in 384-well plates with 1ng/ml of DPPIV.
The system is also suitable for kinetic inhibitor studies.
DPPIV-Glo is available in two pack sizes allowing up to 2000 assays to be performed in 384-well plates.
The assay complements Promega's extensive range of glow-type assays that includes Caspase-Glo, Apo-One, Kinase-Glo and P450-Glo.
